(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property **Organization** International Bureau



(43) International Publication Date 31 March 2005 (31.03.2005)

PCT

(10) International Publication Number WO 2005/028450 A1

- (51) International Patent Classification7: C07D 239/42. A61K 31/505, A61P 3/06
- (21) International Application Number:

PCT/GB2004/004133

(22) International Filing Date:

17 September 2004 (17.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0321827.8

18 September 2003 (18.09.2003)

- (71) Applicant (for all designated States except US): AS-TRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).
- (72) Inventors; and
- (72) Inventors; and
 (73) Inventors/Applicants (for US only): BLACK, Simon, Nicholas [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). OWENS, Lianne [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). MARREN, Kenneth, Edwin, Herbert (GB/GB); AstraZeneca R & D. Alderley, Alderley Park, Macclesfield, Cheshire SK10 2NA (GB). Alderley, Alderley Park, Macclesfield, Cheshire SK10 2NA (GB). Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

 (54)-Fitte: POLYMORPHIC FORMS OF A KNOWN ANTIHYPERLIPEMIC AGENT

 (57) Abstract: Two new polymorphic forms of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrim-thi-1-3-yl](3/K,SS)-3,5-dihydroxyhept-6-en oic acid tris(hydroxymethyl)methylammonium salt (l), processes for making the mand their use in the production of a pharmaceutical useful in the treatment of, inter alia, hypertholesterolemia, hyperthole

- (74) Agent: ASTRAZENECA; Global Intellectual Property, S-151 85 Sodertalje (SE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,

idin-5-yl](3R,5S)-3,5-dihydroxyhept-6-en oic acid tris(hydroxymethyl)methylammonium salt (1), processes for making them and their use in the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis are described.